HealthNovartis reports weaker-than-expected relapse data for MS drug remibrutinib

Novartis said data presented at a medical conference in Toronto showed its oral multiple sclerosis drug remibrutinib meaningfully reduced relapses, but by less than analysts had expected.

Novartismultiple sclerosisremibrutinib

RReuters★★☆☆☆2026-10-23 23:15Original